From Earlier: All-Oral Combination of Investigational Hepatitis C Compounds Daclatasvir and GS-7977 Achieved Sustained Virologic Response in 100% of Genotype 1 and 91% of Genotype 2 and 3 Treatment-Naïve Patients in Phase II Study 